Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial
Diabetes Obesity and Metabolism2022Vol. 24(12), pp. 2364–2372
Citations Over TimeTop 10% of 2022 papers
William H. Polonsky, Francesco Giorgino, Julio Rosenstock, Katherine Whitmire, Elisheva Lew, Mathieu Coudert, Agustina Alvarez, Charlie Nicholls, Rory J. McCrimmon
Abstract
In addition to better glycaemic control, weight benefit and less hypoglycaemia, once-daily iGlarLixi provided improved diabetes management, treatment burden and perceived effectiveness versus twice-daily premix BIAsp 30, further supporting iGlarLixi as an advanced treatment option in people with suboptimally controlled T2D on basal insulin plus OADs.
Related Papers
- → Randomized Controlled Drug Trials on Very Elderly Subjects: Descriptive and Methodological Analysis of Trials Published Between 1990 and 2002 and Comparison With Trials on Adults(2005)36 cited
- An Analysis of Application of Multiple Comparison Tests (Post-Hoc) In ANOVA In Recently Published Medical Research Literature(2015)
- A compatision between one visit RCT and several visit RCT for cracked teeth.(2007)
- Ocular randomized and quasi-randomized contral trial in ophthalmologic journals(2003)
- Basical Clinical Observation of Cracked Tooth with One visit RCT(2003)